Literature DB >> 24145339

Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies.

Kazuki Sudo1, Takashi Taketa, Arlene M Correa, Maria-Claudia Campagna, Roopma Wadhwa, Mariela A Blum, Ritsuko Komaki, Jeffrey H Lee, Manoop S Bhutani, Brian Weston, Heath D Skinner, Dipen M Maru, David C Rice, Stephen G Swisher, Wayne L Hofstetter, Jaffer A Ajani.   

Abstract

PURPOSE: The primary purpose of surveillance of patients with esophageal adenocarcinoma (EAC) and/or esophagogastric junction adenocarcinoma after local therapy (eg, chemoradiotherapy followed by surgery or trimodality therapy [TMT]) is to implement a potentially beneficial salvage therapy to overcome possible morbidity/mortality caused by locoregional failure (LRF). However, the benefits of surveillance are not well understood. We report on LRFs and salvage strategies in a large cohort. PATIENTS AND METHODS: Between 2000 and 2010, 518 patients with EAC who completed TMT were analyzed for the frequency of LRF over time and salvage therapy outcomes. Standard statistical techniques were used.
RESULTS: For 518 patients, the median follow-up time was 29.3 months (range, 1 to 149 months). Distant metastases (with or without LRF) occurred in 188 patients (36%), and LRF only occurred in 27 patients (5%). Eleven of 27 patients had lumen-only LRF. Most LRFs (89%) occurred within 36 months of surgery. Twelve patients had salvage chemoradiotherapy, but only five survived more than 2 years. Four patients needed salvage surgery, and three who survived more than 2 years developed distant metastases. The median overall survival of 27 patients with LRF was 17 months, and 10 patients (37%) survived more than 2 years. Thus, only 2% of all 518 patients benefited from surveillance/salvage strategies.
CONCLUSION: Our surveillance strategy, which is representative of many others currently being used, raises doubts about its effectiveness and benefits (along with concerns regarding types and times of studies and costs implications) to patients with EAC who have LRF only after TMT. Fortunately, LRFs are rare after TMT, but the salvage strategies are not highly beneficial. Our data can help develop an evidence-based surveillance strategy.

Entities:  

Mesh:

Year:  2013        PMID: 24145339      PMCID: PMC3837091          DOI: 10.1200/JCO.2013.51.7250

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  23 in total

1.  Preoperative chemoradiotherapy for esophageal or junctional cancer.

Authors:  P van Hagen; M C C M Hulshof; J J B van Lanschot; E W Steyerberg; M I van Berge Henegouwen; B P L Wijnhoven; D J Richel; G A P Nieuwenhuijzen; G A P Hospers; J J Bonenkamp; M A Cuesta; R J B Blaisse; O R C Busch; F J W ten Kate; G-J Creemers; C J A Punt; J T M Plukker; H M W Verheul; E J Spillenaar Bilgen; H van Dekken; M J C van der Sangen; T Rozema; K Biermann; J C Beukema; A H M Piet; C M van Rij; J G Reinders; H W Tilanus; A van der Gaast
Journal:  N Engl J Med       Date:  2012-05-31       Impact factor: 91.245

2.  Salvage oesophagectomy after local failure of definitive chemoradiotherapy (Br J Surg 2007; 94: 1059-1066).

Authors:  S O'Neill; C Danbury; A Kitching
Journal:  Br J Surg       Date:  2007-12       Impact factor: 6.939

3.  Salvage surgery for esophageal carcinoma after definitive chemoradiation therapy.

Authors:  Hisahiro Matsubara
Journal:  Ann Thorac Cardiovasc Surg       Date:  2007-10       Impact factor: 1.520

Review 4.  [Salvage surgery in esophageal cancer treatment -- its review in this decade and promises for the next decade].

Authors:  Nobukazu Hokamura
Journal:  Gan To Kagaku Ryoho       Date:  2011-02

5.  Esophageal and esophagogastric junction cancers.

Authors:  Jaffer A Ajani; James S Barthel; David J Bentrem; Thomas A D'Amico; Prajnan Das; Crystal S Denlinger; Charles S Fuchs; Hans Gerdes; Robert E Glasgow; James A Hayman; Wayne L Hofstetter; David H Ilson; Rajesh N Keswani; Lawrence R Kleinberg; W Michael Korn; A Craig Lockhart; Mary F Mulcahy; Mark B Orringer; Raymond U Osarogiagbon; James A Posey; Aaron R Sasson; Walter J Scott; Stephen Shibata; Vivian E M Strong; Thomas K Varghese; Graham Warren; Mary Kay Washington; Christopher Willett; Cameron D Wright
Journal:  J Natl Compr Canc Netw       Date:  2011-08-01       Impact factor: 11.908

6.  Salvage esophagectomy after failed definitive chemoradiation for esophageal adenocarcinoma.

Authors:  Jenifer L Marks; Wayne Hofstetter; Arlene M Correa; Reza J Mehran; David Rice; Jack Roth; Garrett Walsh; Ara Vaporciyan; Jeremy Erasmus; Joe Chang; Dipen Maru; Jeffrey H Lee; Jared Lee; Jaffer A Ajani; Stephen G Swisher
Journal:  Ann Thorac Surg       Date:  2012-08-24       Impact factor: 4.330

7.  Outcomes after trimodality therapy for esophageal cancer: the impact of histology on failure patterns.

Authors:  Matthew Koshy; Bruce D Greenwald; Petr Hausner; Mark J Krasna; Naomi Horiba; Richard J Battafarano; Whitney Burrows; Mohan Suntharalingam
Journal:  Am J Clin Oncol       Date:  2011-06       Impact factor: 2.339

8.  Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer.

Authors:  J A Ajani; A M Correa; W L Hofstetter; D C Rice; M A Blum; A Suzuki; T Taketa; J Welsh; S H Lin; J H Lee; M S Bhutani; W A Ross; D M Maru; H A Macapinlac; J Erasmus; R Komaki; R J Mehran; A A Vaporciyan; S G Swisher
Journal:  Ann Oncol       Date:  2012-07-24       Impact factor: 32.976

9.  Salvage esophagectomy following definitive chemoradiotherapy.

Authors:  Mitsuyo Nishimura; Hiroyuki Daiko; Junji Yoshida; Kanji Nagai
Journal:  Gen Thorac Cardiovasc Surg       Date:  2007-11

10.  Salvage esophagectomy for locoregional failure after chemoradiotherapy in patients with advanced esophageal cancer.

Authors:  Changhoon Yoo; Ji Hyun Park; Dok Hyun Yoon; Seung-Il Park; Hyeong Ryul Kim; Jong Hoon Kim; Hwoon-Yong Jung; Gin Hyug Lee; Kee Don Choi; Ho June Song; Ho-Young Song; Ji Hoon Shin; Kyung-Ja Cho; Yong Hee Kim; Sung-Bae Kim
Journal:  Ann Thorac Surg       Date:  2012-09-07       Impact factor: 4.330

View more
  16 in total

1.  Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort.

Authors:  Elena Elimova; Xuemei Wang; Wei Qiao; Kazuki Sudo; Roopma Wadhwa; Hironori Shiozaki; Yusuke Shimodaira; Venkatram Planjery; Nikolaos Charalampakis; Jeffrey H Lee; Brian R Weston; Manoop S Bhutani; Ritsuko Komaki; David C Rice; Stephen G Swisher; Mariela A Blum; Jane E Rogers; Heath D Skinner; Dipen M Maru; Wayne L Hofstetter; Jaffer A Ajani
Journal:  Oncology       Date:  2018-04-27       Impact factor: 2.935

Review 2.  [R1 resection of esophageal carcinoma].

Authors:  I Gockel; C Wittekind
Journal:  Chirurg       Date:  2017-09       Impact factor: 0.955

3.  Barrett's Esophagus after Bimodality Therapy in Patients with Esophageal Adenocarcinoma.

Authors:  Fatemeh G Amlashi; Xuemei Wang; Raquel E Davila; Dipen M Maru; Manoop S Bhutani; Jeffrey H Lee; Brian R Weston; Dilsa Mizrak Kaya; Maria Vassilakopoulou; Kazuto Harada; Mariela A Blum Murphy; David C Rice; Wayne L Hofstetter; Marta Davila; Quynh-Nhu Nguyen; Jaffer A Ajani
Journal:  Oncology       Date:  2018-05-29       Impact factor: 2.935

4.  Distribution and timing of distant metastasis after local therapy in a large cohort of patients with esophageal and esophagogastric junction cancer.

Authors:  Hironori Shiozaki; Kazuki Sudo; Lianchun Xiao; Roopma Wadhwa; Elena Elimova; Wayne L Hofstetter; Heath D Skinner; Jeffrey H Lee; Brian Weston; Manoop S Bhutani; Mariela A Blum; Dipen M Maru; Jaffer A Ajani
Journal:  Oncology       Date:  2014-06-07       Impact factor: 2.935

5.  18F-FDG PET Response After Induction Chemotherapy Can Predict Who Will Benefit from Subsequent Esophagectomy After Chemoradiotherapy for Esophageal Adenocarcinoma.

Authors:  Mian Xi; Zhongxing Liao; Wayne L Hofstetter; Ritsuko Komaki; Linus Ho; Steven H Lin
Journal:  J Nucl Med       Date:  2017-05-18       Impact factor: 10.057

6.  The Invasion and Metastasis of Colon Adenocarcinoma (COAD) Induced by SALL4.

Authors:  Wenjuan Zhang; Yan Hu; Wenbing Zhang; Ke Yi; Xiaohui Xu; Zhihua Chen
Journal:  J Immunol Res       Date:  2022-06-01       Impact factor: 4.493

7.  Geographic distribution of regional metastatic nodes affects the outcome of trimodality-eligible patients with esophageal adenocarcinoma.

Authors:  Hironori Shiozaki; Rebecca Slack; Kazuki Sudo; Elena Elimova; Roopma Wadhwa; Hsian-Chun Chen; Heath D Skinner; Ritsuko Komaki; Jeffrey H Lee; Brian Weston; Manoop S Bhutani; Mariela A Blum; Jane E Rogers; Dipen M Maru; Wayne L Hofstetter; Jaffer A Ajani
Journal:  Oncology       Date:  2015-02-28       Impact factor: 2.935

8.  Consensus statement of the Hellenic and Cypriot Oesophageal Cancer Study Group on the diagnosis, staging and management of oesophageal cancer.

Authors:  Andreas Fountoulakis; John Souglakos; Louiza Vini; Gerasimos N Douridas; Anna Koumarianou; Panteleimon Kountourakis; Christos Agalianos; Andreas Alexandrou; Christos Dervenis; Sofia Gourtsoyianni; Nikolaos Gouvas; Maria-Angeliki Kalogeridi; Georgia Levidou; Theodoros Liakakos; Joseph Sgouros; Spiros N Sgouros; Charikleia Triantopoulou; Evangelos Xynos
Journal:  Updates Surg       Date:  2019-12-02

9.  Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer.

Authors:  Kazuki Sudo; Lianchun Xiao; Roopma Wadhwa; Hironori Shiozaki; Elena Elimova; Takashi Taketa; Mariela A Blum; Jeffrey H Lee; Manoop S Bhutani; Brian Weston; William A Ross; Ritsuko Komaki; David C Rice; Stephen G Swisher; Wayne L Hofstetter; Dipen M Maru; Heath D Skinner; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2014-09-15       Impact factor: 44.544

10.  CTL- vs Treg lymphocyte-attracting chemokines, CCL4 and CCL20, are strong reciprocal predictive markers for survival of patients with oesophageal squamous cell carcinoma.

Authors:  J Y Liu; F Li; L P Wang; X F Chen; D Wang; L Cao; Y Ping; S Zhao; B Li; S H Thorne; B Zhang; P Kalinski; Y Zhang
Journal:  Br J Cancer       Date:  2015-08-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.